الفهرس 
Introduction
systematic reviewOnly 14 pages are availabe for public view
 |  | from | 173 |  |  |
| | | from | 173 | | |
Abstract
Patent ductus arteriosus (PDA) is one of the most common clinical findings and most frequent source of complications in premature infants leading to several undesirable side effects including haemodynamic, pulmonary, cerebral, renal and gastrointestinal disturbances. PDA is conventionally treated by intravenous indomethacin. Intravenous ibuprofen was recently shown to be as effective and to have fewer adverse reactions in preterm infants. If equally effective, then oral ibuprofen for PDA closure would have several important advantages over the intravenous route. Commercially available parental preparations of ibuprofen are more expensive than indomethacine and not available in Egypt where as the oral suspension form is inexpensive and widely used for antipyretic treatment in children. Objectives: The objective of this review is to determine the efficacy and safety of oral ibuprofen in closure of PDA in premature infants when used as an alternative to indomethacin or I.V ibuprofen.